Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

October 24, 2023

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

The scientific community has long appreciated the importance of in vivo tumor models for understanding cancer biology and testing therapeutic strategies. Two popular methods for tumor implantation in these models are orthotopic and subcutaneous implantation. Both have their advantages, and the choice often depends on the specific goals of a study. In this post, we'll delve deep into the benefits of each method to guide researchers in their decision-making process.

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus

In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...

Read more +

The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know

Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.